文献速递急性肾损伤

基因组工程化间充质干细胞无支架细胞片抑制急性肾损伤

A nonbiodegradable scaffold-free cell sheet of genome-engineered mesenchymal stem cells inhibits development of acute kidney injury.
PubMed 文献 · Kidney Int · 2020-08-24

研究利用锌指核酸酶技术将血管生成或抗炎因子基因整合至人脐带间充质干细胞,制成非生物降解温敏聚合物无支架细胞片,贴敷于双侧缺血再灌注急性肾损伤小鼠去包膜肾表面,显著改善肾功能且优于静脉注射相同工程化干细胞。

要点

  • 基因组编辑不影响hUC-MSC分化潜能,细胞片可分泌目标因子。
  • 无支架细胞片贴敷肾表面改善小鼠急性肾损伤肾功能。
  • 细胞片疗效优于静脉注射相同基因组工程化hUC-MSC。

核心结论

  • 基因组工程化间充质干细胞无支架细胞片通过血管生成或抗炎途径抑制急性肾损伤。

研究设计与样本

  • 研究采用双侧缺血再灌注急性肾损伤小鼠模型,使用非生物降解温敏聚合物制备无支架细胞片。

主要发现

  • 细胞片贴敷去包膜肾表面显著改善急性肾损伤小鼠肾功能,效果优于静脉注射相同细胞。

关键数值与推荐

  • 锌指核酸酶辅助整合目标基因经连接PCR验证,流式细胞术和分化实验显示编辑未影响分化潜能。

临床怎么用

  • 为急性肾损伤提供局部细胞治疗新思路,但尚未进入临床。

局限性

  • 仅在小鼠模型验证,未报告长期安全性和临床转化数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cell therapy using genome-engineered stem cells has emerged as a novel strategy for the treatment of kidney diseases. By exploiting genome editing technology, human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) secreting an angiogenic factors or an anti-inflammatory factor were generated for therapeutic application in acute kidney injury. Junction polymerase chain reaction analysis verified zinc finger nucleases-assisted integration of the desired gene into the hUC-MSCs. Flow cytometry and differentiation assays indicated that genome editing did not affect the differentiation potential of these mesenchymal stem cells. Protein measurement in conditioned media with the use of ELISA and immunoblotting revealed the production and secretion of each integrated gene product. For cell therapy in the bilateral ischemia-reperfusion mouse model of acute kidney injury, our innovative scaffold-free cell sheets were established using a non-biodegradable temperature-responsive polymer. One of each type of scaffold-free cell sheets of either the angiogenic factor vascular endothelial grown factor or angiopoietin-1, or the anti-inflammatory factor erythropoietin, or α-melanocyte-stimulating hormone-secreting hUC-MSCs was applied to the decapsulated kidney surface. This resulted in significant amelioration of kidney dysfunction in the mice with acute kidney injury, effects that were superior to intravenous administration of the same genome-engineered hUC-MSCs. Thus, our scaffold-free cell sheets of genome-engineered mesenchymal stem cells provides therapeutic effects by inhibiting acute kidney injury via angiogenesis or anti-inflammation.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Park HJ, Kong MJ, Jang HJ, et al. A nonbiodegradable scaffold-free cell sheet of genome-engineered mesenchymal stem cells inhibits development of acute kidney injury. Kidney Int. 2020. PMID: 32853632. doi:10.1016/j.kint.2020.07.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。